









Markets
/
Stocks
/
nasdaq-stxs
/

Stereotaxis Inc

STXS

2.700USD

+0.020+0.75%

Market hours （ET）Quotes delayed by 15 min

232.20MMarket Cap

LossP/E TTM



Stereotaxis Inc

2.700

+0.020+0.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Stereotaxis Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Stereotaxis Inc's Score

Industry at a Glance

Industry Ranking

101 / 210

Overall Ranking

245 / 4615

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.250

Target Price

+51.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Stereotaxis Inc Highlights

StrengthsRisks

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

Growing

The company is in a growing phase, with the latest annual income totaling USD 26.92M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 26.92M.

Undervalued

The company’s latest PE is -9.44, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 41.74M shares, decreasing 6.59% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.28, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 8.80M, representing a year-over-year increase of 95.42%, while its net profit experienced a year-over-year increase of 32.71%.

Score

Industry at a Glance

Previous score

7.28

Change



Financials

5.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.41

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.43

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.32

Key Metrics

Free cash flow

No Data

Stereotaxis Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.86, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -9.44, which is -45.28% below the recent high of -5.17 and -33.21% above the recent low of -12.58.

Score

Industry at a Glance

Previous score

6.86

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Stereotaxis Inc is 4.00, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.250

Target Price

+58.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Stereotaxis Inc

STXS

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.49, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 3.18 and the support level at 2.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

-0.29

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.093

Sell

RSI(14)

36.987

Neutral

STOCH(KDJ)(9,3,3)

10.351

Oversold

ATR(14)

0.126

Low Volatility

CCI(14)

-127.921

Sell

Williams %R

97.917

Oversold

TRIX(12,20)

-0.302

Sell

StochRSI(14)

21.421

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.776

Sell

MA10

2.883

Sell

MA20

2.974

Sell

MA50

2.961

Sell

MA100

2.677

Buy

MA200

2.365

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fischel (Nathan)

13.92M

+0.31%

Dafna Capital Management, LLC

13.68M

Kiani (Joe E)

8.86M

+5.07%

Lagoda Investment Management, L.P.

4.69M

+7.02%

BlackRock Institutional Trust Company, N.A.

3.60M

+1.92%

The Vanguard Group, Inc.

Star Investors

3.30M

-6.56%

2012 Revocable Trust of Andrew Redleaf

3.08M

Arbiter Partners Capital Management, LLC

2.85M

Isaac (Paul J)

2.05M

Essex Investment Management Company, LLC

1.54M

-0.73%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 3.06, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.